Chevron vs ExxonMobil
CVX and XOM side by side, both in petroleum refining. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVX and XOM compare
ExxonMobil is the larger company, worth 1.7 times as much as Chevron ($770B against $465B).
On earnings, Chevron is cheaper: it trades at 22.6× trailing earnings, against 24.1× for ExxonMobil.
Chevron grew revenue faster over the last twelve months (10.2% versus 9.1% for ExxonMobil).
Chevron keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with 8.9% at ExxonMobil.
Both pay dividends: Chevron yields 3.0% and ExxonMobil 2.2%.
Chevron scores higher on the StockData Score (12 against 11 for ExxonMobil), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVX | XOM |
|---|---|---|
| Size and price | ||
| Market cap | $465B | $770B |
| Share price | $235.52 | $187.25 |
| Change, 1 year | 51.9% | 60.8% |
| Change, 5 years | 105% | 188% |
| Beta (5Y) | 0.38 | 0.27 |
| Employees | 4,645 | 58K |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 22.6× (better) | 24.1× |
| P/S | 2.2× | 2.1× (better) |
| P/B | 2.5× (better) | 3.0× |
| EV/EBITDA | 8.3× (better) | 10.7× |
| P/FCF | 17.2× (better) | 25.2× |
| FCF yield | 5.8% (better) | 4.0% |
| Fair value | $195.40 | $134.59 |
| Margin of safety | −20.5% (better) | −39.1% |
| Growth | ||
| Revenue growth (TTM) | 10.2% (better) | 9.1% |
| Revenue growth, 5Y average | 14.8% (better) | 12.9% |
| Net income growth (TTM) | 50.1% (better) | 5.6% |
| EPS growth (TTM) | 34.6% (better) | 10.4% |
| Profitability | ||
| Gross margin | 45.4% | – |
| Net margin | 9.6% (better) | 8.9% |
| FCF margin | 12.5% (better) | 8.3% |
| Return on equity | 12.2% | 12.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.16 |
| Net debt / EBITDA | −0.17 | 0.42 (better) |
| Current ratio | 1.25 (better) | 1.13 |
| Altman Z-score | 3.66 | 4.64 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 3.0% (better) | 2.2% |
| Payout ratio | 67.3% | 52.6% |
| Years of dividend growth | 6 | 16 (better) |
| Dividend growth, 5Y average | 5.8% (better) | 2.8% |
| Buyback yield | 2.4% | 2.7% (better) |
| Shareholder yield | 5.4% (better) | 4.9% |
| Ownership | ||
| Held by institutions | 74.3% | 66.0% |
| Held by insiders | 0.34% | 0.00% |
| Insider net buying, 12 months | −$637M | – |
| Superinvestors holding | 4 (better) | 3 |
| Short interest, % of float | 1.2% | 0.95% |
Go deeper
- CVX stock overview
- CVX income statement
- CVX valuation and score
- XOM stock overview
- XOM income statement
- XOM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.